Skip to content

Erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy

Erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN33604417
Enrollment
9
Registered
2018-09-14
Start date
2014-02-07
Completion date
Unknown
Last updated
2019-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal hypoxic-ischemic encephalopathy Neonatal Diseases Hypoxic ischaemic encephalopathy of newborn

Interventions

A combination therapy with erythropoietin (300 mg/kg every other day for 2 weeks), magnesium sulfate (250 mg/kg for 3 days) and hypothermia was started within 6 hours of birth in neonates who met the

Sponsors

Osaka City General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Neonates admitted to the Osaka City General Hospital Neonatal Intensive Care Unit (NICU) and diagnosed with HIE, meeting institutional criteria for therapeutic hypothermia

Exclusion criteria

Exclusion criteria: 1. Infants older than 6 hours of birth at the time of initiation of hypothermia therapy 2. Infants with major congenital abnormalities 3. Infants with severe growth restriction with birth weight less than 1800 g 4. Infants who were considered critically ill and unlikely to bene?t from neonatal intensive care by the attending neonatologist

Design outcomes

Primary

MeasureTime frame
Mortality and morbidity in neonatal period, measured by clinical records regarding in-hospital death, establishment of oral feeding, establishment of spontaneous respiration and brain MRI findings at 1 month of age

Secondary

MeasureTime frame
Neurodevelopmental outcome measured using the Kyoto Scale of Psychological Development (KSPD) at 18 months of age

Countries

Japan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 4, 2026